

Methods for the Treatment of Vitiligo Patches including UV Radiation and other Therapies.

B.H.PAWAR, A.S.LAD*, S. S. ARSAD **, U.R. KATHALE

Email: arsadswapnil@yahoo.co.in

*Dept. of phy., Amolakchand Mahavidyalaya, Yavatmal

**Dept. of phy. Shri Shivaji Science College Amravati

Abstract

Vitiligo is a common hypopigmentation disorder disease that causes a great degree of psychological distress. In its classical forms it is easily recognised and diagnosed. This review discusses the methods for the treatment of vitiligo patches which are based on evidence. The treatment of vitiligo is a long term process which may lead to unsatisfactory results if the treatment is abandoned by the patient. A definite diagnosis, offering psychological support and suggesting supportive treatments is the main requirement of patient. A pilot study was conducted which included visit to clinics, trials and feedback from patients to determine the present methodology being used for the treatment. The review is reported here.

Keywords: Treatment, Vitiligo Patches, UV Radiation, Therapies

Background

Vitiligo is a depigmentation disorder affecting 1-2% of the world population. Fifty percent of cases appear before the age of 20, with the disfigurement resulting in psychiatric morbidity in 16 to 35% of those affected. Depression, sleep disturbances, suicidal thoughts, suicidal attempts, difficulties in relationships and avoidance of social situations have been reported in individuals afflicted by vitiligo before adulthood. Vitiligo can be confused with leprosy, leading to further stigmatization.

The disease pathogenesis of vitiligo has not been fully elucidated. Autoimmune, biochemical and oxidative stress, genetic, neuronal and environmental factors are thought to interact and contribute to the development of vitiligo ⁷. Forschner points to four distinct theories ¹². The first is an "autoimmune hypothesis" supported by the observation that several autoimmune diseases often appear along with vitiligo ⁸. In addition, vitiligo sufferers often display elevated levels of serum antibodies to melanocytic antigens (tyrosinase and tyrosinase-related proteins 1 and 2) ^{11,12}. Second is the "neuronal hypothesis" which states that altered reactions of melanocytes to neuropeptides and catecholamines are responsible for melanocyte destruction ¹². Several studies have found that dopamine can induce apoptosis in human melanocytes ^{13,14}.

The neuronal hypothesis is further supported by the findings that there is close contact between melanocytes and nerve endings in depigmented skin, an observation rarely seen in normal skin¹². Third is the "self-destruct hypothesis", where melanocytes self-destruct due to defects in protective mechanisms responsible for removing toxic melanin precursors. This is thought to lead to the accumulation of melanotoxic indole derivatives and free radicals. Fourth is the "biochemical hypothesis" which postulates an overproduction of a tyrosine hydroxylase cofactor, hydrobiopterin, resulting in increased catecholamine synthesis. This is thought to result in increased reactive oxygen species that are toxic to melanocytes. This is supported by findings of reduced catalase and higher concentrations of hydrogen peroxide in affected and unaffected skin of vitiligo sufferers^{12,15}.

Methods

The study comprised of 4 visits: initial, and 3 follow up visits every 4 weeks. Total length of treatment was 12 weeks for each participant pursuing vitiligo treatment in Ayurvedic, Homeopathic, Allopathic and Phototherapy clinics.

During the initial visit the patients registered with the skin specialist were checked and their data was collected. presence of vitiligo was verified under Wood's lamp at few clinics. Inclusion and exclusion criteria were assessed, which excluded anyone who had treatment for greatest, and those who did not improve at all. Of the three participants that improved the greatest: two had progressive vitiligo, while one had non progressive; two were male, one was female; two had Fitzpatrick's skin type 5 and one Fitzpatrick skin type 4. They were 56, 14 and 19 years old, and had suffered with vitiligo for 12, 7 and 3 years and had started treatment between June-July 2011 respectively. One had vitiligo on hands, the others did not. Two had vitiligo on the torso and all three had vitiligo on the lower body but only one on feet.

Conclusions

The methods which are currently used have some common criterion like checking the pathogenesis, tropical treatment creams, oral drugs, diet instructions etc are followed by all the clinics. Participant retention, safety and effectiveness criteria were also met by the clinics. Herbal medicine like Ingestion of 60 mg of *Ginkgo biloba* BID is used at some places. Conventional treatments for vitiligo include photochemotherapy (PUVA), phototherapy (UVB), vitamin D3 analogues, topical corticosteroids, topical immunomodulators, excimer laser, and surgery. These treatment options have limited success^{1,7,8}, and some present significant risks by PUVA, skin atrophy with corticosteroids, and skin erythema with UVB therapy^{1,7,8}. The therapy with high benefit and low risk is preferred. The psychological impact of vitiligo make the search for a safe and effective alternative approach critical.

A systematic review of natural health product (NHP) treatments for vitiligo¹² identified several approaches showing positive results, including topical tocopherol, topical vitamin D3¹², and oral l-phenylalanine and *Ginkgo biloba*. However, the trials were generally of poor quality and the products

were often tested as adjuncts to UVA or UVB. One trial using only *UV radiation* in adults showed promising results with good methodological quality.

Most studies of vitiligo treatment with phototherapy set a 75% repigmentation rate as cosmetically acceptable, and are able to achieve it in 12.5 to 75% of patients after one year of treatment¹⁷. By comparison, other studies have found a 43% improvement with narrow band UVB therapy¹⁸.

References

1. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian Journal of Dermatology, Venerology and Leprology. 2007;73(3):149–156.
2. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clinical & Experimental Dermatology. 2003;28(3):285–287.
3. Halder RMMDa, Nootheti PKMDb. Ethnic skin disorders overview. [Miscellaneous] Journal of the American Academy of Dermatology. 2003;48((6 Part 2) Supplement):S143–S148.
4. Behl PN, Bhatia RK. 400 cases of vitiligo - A clinicotherapeutic analysis. Indian Journal of Dermatology. 1971;17:51–53.
5. Mehta HR, Shah KC, Theodore C. Epidemiological study of vitiligo in Surat area, South Gujarat. Indian Journal of Medical Research. 1973;61:145–154.
6. Ongenaes K, Beelaert L, Van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. Journal of the European Academy of Dermatology & Venereology. 2005;20:1–8.
7. Grimes PEMD. New Insights and New Therapies in Vitiligo. [Miscellaneous Article] JAMA. 2005;293(6):730–735.
8. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy--evidence-based analysis of the literature. [Review] [30 refs] Journal der Deutschen Dermatologischen Gesellschaft. 2007;5(6):467–475.
9. Chu CY, Liu YL, Chiu HC, Jee SH. Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. British Journal of Dermatology. 2006;154(6):1071–1079.
10. Park ES, Kim SY, Na JI, Ryu HS, Youn SW, Kim DS, Yun HY, Park KC. Glutathione prevented dopamine-induced apoptosis of melanocytes and its signaling. Journal of Dermatological Science. 2007;47(2):141–149.
11. Namazi M, Chee Leok G. Vitiligo and diet: a theoretical molecular approach with practical implications. Indian Journal of Dermatology, Venerology and Leprology. 2009;75(2):116–118.

12. Szczurko O, Boon H. A systematic review of natural health product treatment for vitiligo. *BMC Dermatology*. 2008;8(2)
13. Panin Ga, Strumia Rb, Ursini Fc. Topical [alpha]-Tocopherol Acetate in the Bulk Phase: Eight Years of Experience in Skin Treatment. [Article] *Annals of the New York Academy of Sciences*. 2004;1031:443–447.
14. Ichiro K, Aki MA, Kumiko E, Sang JB. Vitamin D3 and solar irradiation in the treatment of vitiligo vulgaris. [Miscellaneous] *Journal of the European Academy of Dermatology & Venereology Supplement*. 2002;16(Supplement 1):341.
15. Woelk H, Arnoldt K, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. *Journal of Psychiatric Research*. 2007;41:472–480.
16. Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. *Pigment Cell Research*. 2007;20:27–35.
17. Nicolaidu E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. *Journal of the American Academy of Dermatology*. 2009;60(3):470–477.
18. Scherschun L, Kim J, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. *J Am Acad Dermatol*. 2001;44(6):999–1003.